What's Happening?
Biocom, the largest life science membership association representing companies across California and major life science markets globally, has announced the appointment of Zachary Hornby and Kevin Marks
to its board of directors. Zachary Hornby is the chief executive officer and a director of Callio Therapeutics, a clinical-stage company specializing in dual-payload antibody-drug conjugates. His extensive background includes leading Boundless Bio through a $350 million fundraising and IPO, and overseeing Ignyta's $2 billion acquisition by Roche. Kevin Marks serves as the chief legal officer at Parker Institute, where he manages legal, intellectual property, and human resources functions. Previously, he was general counsel at the California Institute for Regenerative Medicine (CIRM) and spent over 20 years at Roche, leading legal and compliance teams and managing global litigation. Tim Scott, president and CEO of Biocom, stated that both individuals bring valuable experience in translating scientific breakthroughs into successful companies and treatments, which is crucial for Biocom's mission.
Why It's Important?
The appointment of Zachary Hornby and Kevin Marks to Biocom's board is important for the U.S. life sciences industry, particularly in California. Their combined expertise in business development, legal strategy, and bringing innovative therapies to market will significantly strengthen Biocom's ability to support its member companies. Hornby's experience with IPOs and major acquisitions provides critical insights for emerging biotech firms seeking funding and strategic partnerships. Marks's extensive legal and intellectual property background is invaluable for navigating the complex regulatory landscape and protecting innovation in the highly competitive life sciences sector. These appointments will help Biocom better advocate for policies that foster innovation, facilitate access to capital, and strengthen the talent pipeline, ultimately contributing to the growth and competitiveness of the U.S. life sciences ecosystem. Their leadership will be instrumental in guiding Biocom's strategy as it expands its reach and influence.
What's Next?
With the addition of Zachary Hornby and Kevin Marks, Biocom's board of directors will likely focus on leveraging their expertise to enhance the association's strategic initiatives. This could involve developing new programs to support member companies in areas such as fundraising, intellectual property protection, and regulatory compliance. Their insights will be crucial in shaping Biocom's advocacy efforts to influence policy decisions that impact the life sciences industry. The association will continue its work in driving innovation, fostering industry competitiveness, and strengthening talent pipelines across its diverse membership, which includes biotechnology, pharmaceutical, medical device, genomics, and diagnostics companies. The new board members are expected to play a key role in guiding Biocom's expansion into new markets and its efforts to connect regional ecosystems with global opportunities.
Beyond the Headlines
The addition of these high-caliber individuals to Biocom's board reflects the increasing complexity and strategic demands of the life sciences industry. Beyond their direct contributions, their appointments signal a broader trend towards integrating deep business and legal acumen with scientific innovation to drive commercial success. This move highlights the critical importance of strong leadership in navigating the challenges of drug development, market access, and intellectual property in a globalized environment. It also underscores the role of industry associations like Biocom in providing a platform for collaboration and knowledge sharing, which is essential for maintaining the U.S.'s leadership in life sciences. The expertise of Hornby and Marks will not only benefit Biocom's members but also contribute to the overall health and growth of the U.S. bio-economy, impacting patient care and technological advancements.








